Transcatheter Aortic Valve Replacement (TAVR)

Transcatheter aortic valve replacement (TAVR) is a minimally invasive cardiac procedure that replaces a diseased aortic valve without open-heart surgery, using a catheter-delivered prosthetic valve advanced through a blood vessel — most commonly the femoral artery. This page covers the procedural mechanism, patient selection criteria, clinical scenarios where TAVR is applied, and the boundaries that determine when surgical aortic valve replacement (SAVR) remains the preferred option. Understanding TAVR's scope matters because aortic stenosis is the most common valvular heart disease requiring intervention in adults over age 65 in the United States, and the procedural landscape is governed by overlapping clinical guidelines and federal coverage determinations. For a broader look at the treatment environment, the regulatory context for cardiology page addresses the policy structures that shape how these procedures are approved and reimbursed.

Definition and Scope

TAVR addresses severe aortic stenosis — a narrowing of the aortic valve opening that restricts blood flow from the left ventricle into the aorta. The native valve is not surgically removed; instead, the prosthetic valve is crimped onto a delivery catheter, advanced to the aortic annulus, and expanded either by balloon inflation or by self-expanding mechanism, compressing the diseased leaflets against the vessel wall.

The U.S. Food and Drug Administration (FDA) has cleared TAVR systems from two primary manufacturers for broad clinical use: Edwards Lifesciences (SAPIEN valve family) and Medtronic (CoreValve/Evolut family). Both received expanded FDA indications over successive approval cycles — from high-surgical-risk patients initially to intermediate- and low-surgical-risk patients by 2019 (FDA Device Approvals).

The Centers for Medicare & Medicaid Services (CMS) governs reimbursement through a National Coverage Determination (NCD 20.32), which requires procedures to be performed at facilities meeting specific structural heart program criteria and mandates participation in a data registry — the Society of Thoracic Surgeons/American College of Cardiology (STS/ACC) TVT Registry (CMS NCD 20.32).

Heart valve disease encompasses multiple conditions beyond aortic stenosis, but TAVR's clinical development has been concentrated specifically on that lesion, making it a defined subset of the broader heart valve repair and replacement category.

How It Works

The TAVR procedure follows a structured sequence:

  1. Pre-procedural imaging — Cardiac CT angiography of the aortic annulus, iliofemoral vasculature, and coronary ostia establishes annular dimensions and access route suitability. Annular diameter measurement guides valve sizing, typically in millimeters corresponding to manufacturer-specific sizing charts.
  2. Access selection — The transfemoral approach (through the femoral artery in the groin) is the default and accounts for the majority of contemporary TAVR cases. Alternative access sites — transapical, transaortic, transaxillary/subclavian, and transcaval — are used when femoral anatomy is prohibitive.
  3. Valve delivery and deployment — Under fluoroscopic and echocardiographic guidance, the crimped prosthesis is advanced across the diseased native valve. Balloon-expandable valves (SAPIEN family) are deployed by rapid balloon inflation; self-expanding valves (CoreValve/Evolut) are released by catheter retraction and expand over seconds.
  4. Post-deployment assessment — Aortography and transesophageal echocardiography (TEE) evaluate valve position, paravalvular leak grade, and coronary flow.
  5. Conduction monitoring — New left bundle branch block or complete heart block requiring permanent pacemaker implantation is a recognized complication; published registry data from the STS/ACC TVT Registry report pacemaker implantation rates in the range of 8–25% depending on valve type and patient anatomy (STS/ACC TVT Registry).

The procedure is performed in a hybrid operating room or cardiac catheterization laboratory equipped for conversion to open surgery if required.

Common Scenarios

TAVR is applied across four main clinical scenarios defined by surgical risk classification and anatomical context:

High surgical risk — Patients with an STS Predicted Risk of Mortality (PROM) score ≥8% or documented frailty indices placing operative mortality at prohibitive levels. This was the original indication in landmark trials including PARTNER 1 (Edwards SAPIEN, published 2011) and CoreValve High Risk Study (2014).

Intermediate surgical risk — STS PROM scores of 4–8%. PARTNER 2A and SURTAVI trials demonstrated non-inferiority to SAVR in this population, supporting expanded FDA labeling.

Low surgical risk — STS PROM below 4%. PARTNER 3 and Evolut Low Risk trials, both published in 2019 in the New England Journal of Medicine, showed TAVR met non-inferiority endpoints against surgery, leading to FDA label expansion and CMS coverage policy updates.

Valve-in-valve TAVR — Patients with prior surgical bioprosthetic aortic valve failure who require re-intervention. Rather than re-operative surgery, a transcatheter valve is deployed within the failed surgical prosthesis.

Decision Boundaries

Determining TAVR versus SAVR involves a multidisciplinary Heart Team evaluation — a structural requirement under CMS NCD 20.32 — assessing anatomical, physiological, and patient-preference factors.

Factors favoring TAVR:
- Elevated surgical risk (STS PROM ≥4% or clinical frailty)
- Femoral access feasibility confirmed by CT
- Patient preference for avoiding sternotomy and cardiopulmonary bypass
- Prior chest radiation limiting surgical planes

Factors favoring SAVR:
- Age under 65 with projected need for multiple future valve interventions (durability data for transcatheter valves beyond 10 years remains limited)
- Anatomy requiring concomitant coronary artery bypass or other structural repair not addressable transcutaneously
- Bicuspid aortic valve morphology — not an absolute contraindication, but outcomes data are less mature than for tricuspid valves
- Annular dimensions outside the range of available transcatheter prosthesis sizes

The ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease (2021 revision) assigns a Class I recommendation to TAVR for patients with severe symptomatic aortic stenosis at high or prohibitive surgical risk, and a Class IIa recommendation at intermediate risk (ACC/AHA 2021 Valvular Heart Disease Guideline). For low-risk patients, the guideline assigns Class IIa based on patient anatomy and preference, reflecting ongoing follow-up of long-term durability data.

Patients eligible for cardiac catheterization and angiography workup are commonly evaluated in the same procedural pipeline as TAVR candidates, since coronary anatomy assessment is a mandatory component of pre-TAVR planning. Cardiologyauthority's index provides orientation to the full scope of cardiovascular conditions and procedures covered across this resource.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)